PMID: 42309121
1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.
Leslie Daniel B, Steffen Brian T, Wise Eric et al.
The lancet. Diabetes & endocrinology · 2026
Research Library
Tirzepatide
237 papers indexed
PMID: 42326176
A Case of an Invisible Pancreatic Neuroendocrine Tumor Decoded by Endoscopic Ultrasound.
Joseph Jenny, Nasir Syed Alishan, Mangla Rakhee
Cureus · 2026
PMID: 42410323
A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.
Zhang Yunxiao, Zhu Bo, Peng Binhui et al.
Diabetes, obesity & metabolism · 2026
PMID: 42250890
A subphenotype of obesity with reduced enteroendocrine GLP-1 synthesis and enhanced tirzepatide response.
Ticho Alexander L, McRae Alison N, Cifuentes Lizeth et al.
Gastroenterology · 2026
PMID: 42372355
A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model.
Liu Yuxuan, Liu Xiaojun
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026
PMID: 42530904
Abrupt Smoking Cessation Due to Sensory Aversion Following Tirzepatide Initiation.
Ceesay Omar I, Rokusek Blase, Rasmussen Jordan et al.
The primary care companion for CNS disorders · 2026
PMID: 42569780
Acute Unilateral NAION following Tirzepatide Therapy: A Case Report.
Valášková Jela, Bondarchuk Dmytro, Kadlic Peter et al.
Case reports in ophthalmology · 2026
PMID: 42170166
Addressing Tamoxifen-Associated Weight Gain: Lifestyle and Pharmacotherapy Options.
Fore-Williams Latonya, Distler Michele
Journal of the advanced practitioner in oncology · 2026
PMID: 42309434
Adjunctive GLP1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.
Yeh Kuan-Hung, Ahuja Dhruv, Patel Sagar B et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
PMID: 42206886
After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care.
Zucker Anna
Journal of medical Internet research · 2026
PMID: 42560457
Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
Pałka Wiktoria, Moćko Paweł, Śladowska Katarzyna et al.
Journal of endocrinological investigation · 2026
PMID: 42326458
Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection.
Singh Neha, Chaparro Elisa, Shapiro Jordan Michael et al.
ACG case reports journal · 2026
PMID: 42254821
Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea.
Preshy Anish, Fernandez Cornelius J, Nedai Mohammad Hamid et al.
Chronic diseases and translational medicine · 2026
PMID: 42481079
Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
Rodriguez Patricia J, Lusk Jay B, Mehta Hemalkumar B et al.
BMJ open · 2026
PMID: 42424619
Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.
Frey Connor, Etminan Mahyar
Obstetrics and gynecology · 2026
PMID: 42383218
Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study.
Pan Ssu-Yu, Weng Chien-Hsiang, Sheen Yi-Jing et al.
Ophthalmology science · 2026
PMID: 42543696
Atypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide.
Saito Chiaki, Saito Masahiro, Nakagawa Masatoshi et al.
Internal medicine (Tokyo, Japan) · 2026
PMID: 42296503
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Damen Johanna A A, Idema Demy L, Vernooij Robin W M et al.
Annals of internal medicine · 2026
PMID: 42278283
Benefits of Incretin Therapy on Ovarian Function: A Scientific Literature Review.
La Vignera Sandro, Condorelli Rosita A
International journal of molecular sciences · 2026
PMID: 42534427
Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.
Alawad Azza O, Merghani Tarig H, Fadelelmoula Tarig E et al.
Therapeutic advances in endocrinology and metabolism · 2026
PMID: 42208956
Beyond weight loss: multisystem benefits of obesity medications.
Savas Mesut, Kuckuck Susanne, Boon Mariëtte R et al.
The lancet. Diabetes & endocrinology · 2026
PMID: 42388883
Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study.
Kapan Ali, Moser Othmar, Felsinger Richard et al.
Frontiers in endocrinology · 2026
PMID: 42247569
Biomimetic Hematoma Enables Healing in Complex Periprosthetic Fracture Nonunion with Multiple Comorbidities: A Case Report.
Maestas Adam, Glatt Vaida, Alderete Joseph F
JBJS case connector · 2026
PMID: 42124628
Brca1 heterozygosity leads to hepatic steatosis in male and female mice despite sexually dimorphic effects on systemic metabolism.
Palikhe Sailesh, Qiao Linlan, Kutz Caleb et al.
bioRxiv : the preprint server for biology · 2026
PMID: 42483841
Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.
Rashid Muhammed, Lee E Lyn, Veettil Sajesh K et al.
Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
PMID: 42211143
Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus.
Terui Sakiko, Minami Taichi, Nakamura Keita et al.
Journal of lipid and atherosclerosis · 2026
PMID: 42489387
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
Azzam Ahmed Y, Essibayi Muhammed Amir, Rai Pranjal et al.
JACC. Advances · 2026
PMID: 42316327
Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
Zhou Xiao-Yu, Wu Qi, Lu Hao-Lan et al.
Diabetology & metabolic syndrome · 2026
PMID: 42422421
Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation.
Tanaka Yuri, Ueno Hiroaki, Sawada Hirotake et al.
Frontiers in endocrinology · 2026
PMID: 42541308
Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use.
Peng Dorothy S, Shen Amy, Smart Chandra et al.
JAAD case reports · 2026
PMID: 42168641
Causes and consequences of discontinuation of GLP1RAs or tirzepatide.
Ceriello Antonio, Prattichizzo Francesco, Mastan Sheik Abdullah Abdul Raouf et al.
Nature reviews. Endocrinology · 2026
PMID: 42453843
Cellulite as a Possible Biomarker of Metabolic Dysfunction: Redefining Body Remodeling in the Glucagon-Like Peptide-1 Era Through the Cellulite Removal Medical Protocol-G21 Concept.
Adamidis Nikos, Adamidi Sofia, Georgakopoulou Vasiliki E et al.
Cureus · 2026
PMID: 42412744
Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses.
Kanu Chisom, Shinde Shraddha, Falcon Beverly et al.
Sleep · 2026
PMID: 42575344
Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes.
Dziewierz Artur, Kulicka Natalia, Łupina Krzysztof et al.
Diabetes research and clinical practice · 2026
PMID: 42388957
Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review.
Mady Raafat, Tafazal Habib, Soliman Haitham et al.
Cureus · 2026
PMID: 42373761
Clinical benefits of tirzepatide in patients with steatotic liver disease and cardiometabolic dysfunction.
Shiau Bo-Wen, Hsu Wan-Hsuan, Kuo Chia-Chih et al.
Communications medicine · 2026
PMID: 42244870
Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease.
Wu Jheng-Yan, Lin Yu-Min, Hsu Wan-Hsuan et al.
Frontiers in pharmacology · 2026
PMID: 42160590
Comment on Sattar et al. Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2. Diabetes Care 2025;48:e136-e137.
Corrao Salvatore
Diabetes care · 2026
PMID: 42466510
Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
Wu Jheng-Yan, Lee Keng-Wei, Kao Chia-Li et al.
Journal of the American Heart Association · 2026
PMID: 42207966
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
Hamarsheh Sultan, Jaber Abdel Rahman, Abu-Khazneh Omar et al.
Endocrinology, diabetes & metabolism · 2026
PMID: 42209204
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.
Wachiraphansakul Nuttaya, Vongchaiudomchoke Thanawat, Manosroi Worapaka et al.
Diabetes, obesity & metabolism · 2026
PMID: 42487213
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Kamrul-Hasan A B M, Khalil Ibrahim, Dutta Deep et al.
Endocrinology, diabetes & metabolism · 2026
PMID: 42211533
Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications.
Baba Azhar Hafiz, Akhtar Rameez, Rawat Anurag et al.
Nepal journal of epidemiology · 2026
PMID: 42420805
Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure.
Mortada Ibrahim, Paul Krishna, Chammany Michael et al.
Diabetes & vascular disease research · 2026
PMID: 42419792
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
Nong Kailei, Shi Qingyang, Xie Xinran et al.
BMJ (Clinical research ed.) · 2026
PMID: 42376874
Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.
Qadeer Abdul, Khalid Marwah Bintay, Syed Ridwan et al.
Diabetes & vascular disease research · 2026
PMID: 42117113
Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery.
Nanah M Housam, Chatterjee Arjun, Wehbe Hisham et al.
Crohn's & colitis 360 · 2026
PMID: 42532547
Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.
Venerito Vincenzo, Lopalco Giuseppe, Colaprico Cristiana et al.
RMD open · 2026
PMID: 42469143
Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
Zhou Xiao-Yu, Deng Chen-Hao, Zhong Ji-Yuan et al.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026
PMID: 42388932
Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review.
Mady Raafat, Tafazal Habib, Soliman Haitham et al.
Cureus · 2026
PMID: 42137317
Correction: Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis.
Provenzani Alessio, Mancuso Brinn, Stitch Riley et al.
Frontiers in pharmacology · 2026
PMID: 42151574
Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide.
Schmickl Christopher N, Tripipitsiriwat Athiwat, Mokhlesi Babak et al.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
PMID: 42296505
Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.
Jenniskens Kevin, Huis In 't Veld Linde F, Lokerse Marle E et al.
Annals of internal medicine · 2026
PMID: 42155673
Cost-effectiveness and budget-impact analysis of tirzepatide in heart failure with preserved ejection fraction and obesity in the German health-care system.
Estler Bent, Fröhlich Hanna, Täger Tobias et al.
International journal of cardiology · 2026
PMID: 42211692
DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.
Sasset Linda, Cameron Andrew D, Sussman Carleigh et al.
Molecular therapy. Nucleic acids · 2026
PMID: 42159298
DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic fabry disease.
Riccio Eleonora, Cuomo Alessandra, Capuano Ivana et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
PMID: 42530676
Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.
Vishnoi Shubham, Hudson Sarah, Bhattacharya Shayon et al.
Journal of computer-aided molecular design · 2026
PMID: 42123715
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis.
Liang Chih-Sung, Hsu Chih-Wei, Chen Jiann-Jy et al.
International journal of molecular sciences · 2026
PMID: 42207410
Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.
Alvina, Jaffar Huda, Onwuzo Chidera N et al.
Digestive diseases and sciences · 2026
PMID: 42315695
Differential impact of pre-operative tirzepatide compared to glucagon-like-peptide-1 single receptor agonists on outcomes of spinal fusion surgery in obese patients.
Sacks Gregory Isaac, Meydan Yoli, Lebens Ryan et al.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
PMID: 42125916
Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution.
Zhang Nan, Teng Li, Yu Xiang et al.
Journal of medicinal chemistry · 2026
PMID: 42248357
Disproportionality Analysis of Tirzepatide-Associated Ketoacidosis.
Frey Connor
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
PMID: 42421032
Disrupting the adiposopathy-inflammation loop: a translational immunometabolic framework for inflammatory disease.
Corrao Salvatore
Journal of translational medicine · 2026
PMID: 42449760
Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide?
La Vignera Sandro, Fioriglio Cristian, Condorelli Rosita A
Diagnostics (Basel, Switzerland) · 2026
PMID: 42252377
Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.
Builes-Montaño Carlos E, Suarez-Rodriguez Andres F, Alzate-Vinasco Maria A
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
PMID: 42249304
Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.
Pan Yongning, Song Fanfan, Liu Xuehua et al.
BMC gastroenterology · 2026
PMID: 42256584
Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care.
Samajdar Shambo Samrat, Joshi Shashank, Saboo Banshi et al.
Diabetology international · 2026
PMID: 42168638
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
Laroche Marie-Laure, Géniaux Hélène, Jardou Manon
European journal of clinical pharmacology · 2026
PMID: 42155604
Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation.
Fauchier Laurent, Guglieri Mickael
Diabetes research and clinical practice · 2026
PMID: 42275945
Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study.
Angelopoulos Nikolaos, Rizoulis Andreas, Boniakos Anastasios et al.
Nutrition (Burbank, Los Angeles County, Calif.) · 2026
PMID: 42530338
Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.
Silverii Giovanni Antonio, Velardi Valerio, Marinelli Christian et al.
Diabetes, obesity & metabolism · 2026
PMID: 42464179
Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.
Demircan Fatih, Ozozan Omer Vefik, Gozel Nevzat
BMC endocrine disorders · 2026
PMID: 42289805
Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data.
Abe Tomoe, Maruyama Fumika, Nishikawa Eisuke et al.
Journal of diabetes investigation · 2026
PMID: 42452586
Effects of GLP-1 Receptor Agonists on Psoriasis: An "Agent-Specific" Systematic Review of the Literature.
Marani Andrea, Neri Eleonora, Morea Edvige et al.
Journal of clinical medicine · 2026
PMID: 42417681
Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.
Borlaug Barry A, Zile Michael R, Kramer Christopher M et al.
JACC. Heart failure · 2026
PMID: 42488012
Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity.
Corso Haley, Graybeal Austin J, Hoelscher Emily et al.
Frontiers in endocrinology · 2026
PMID: 42378200
Endotypic trait responses to 12-month tirzepatide treatment for an obese patient with obstructive sleep apnea: a case report.
Hsu Yen, Cheng Wan-Ju, Finnsson Eysteinn et al.
Obesity facts · 2026
PMID: 42131414
Evaluating the antidepressant effects of tirzepatide on unpredictable chronic mild stress-induced depression in Swiss Albino mice.
Maradia Jay, Joshi Shirish Shashikant, Koli Paresh et al.
Tzu chi medical journal · 2026
PMID: 42383939
Evaluation of the Clinical Effectiveness and Cost-Effectiveness of Tirzepatide for Type 2 Diabetes in Canada Using Bayesian Transportability Analysis.
Metcalfe Rebecca K, Yan Yichen, Alam Shomoita et al.
Value in health regional issues · 2026
PMID: 42207473
Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.
Anatriello Antonietta, Liguori Valerio, Pentella Ciro et al.
Pharmacological reports : PR · 2026
PMID: 42165732
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.
Gupta Monika, Shukla Jitendra
The Indian journal of medical research · 2026
PMID: 42467193
Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.
Kozato Akio, Patel Suhani S, Orandi Babak J et al.
Surgical endoscopy · 2026
PMID: 42334799
Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study.
Kiyosue Arihiro, Sato Manaka, Cai Zhihong et al.
Advances in therapy · 2026
PMID: 42158845
Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data.
Alourfi Nouf M, Alorfi Nasser M
Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
PMID: 42559252
From Weight Loss to Organ-Specific Disease Modification: A Narrative Review of Incretin-Based Therapies in Obesity-Related Cardiometabolic Disease, Chronic Kidney Disease, Metabolic Dysfunction-Associated Steatohepatitis, and Obstructive Sleep Apnoea.
Joshi Devarsh
Cureus · 2026
PMID: 42453677
Functional segregation of body-brain signals in the area postrema.
López-Cruz Alejandro, Figueredo Burgos Natalie S, Hakimi Anna M et al.
bioRxiv : the preprint server for biology · 2026
PMID: 42209267
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology.
De Fano Michelantonio, Haurum Line L, Schwarz Christine R et al.
Diabetes, obesity & metabolism · 2026
PMID: 42318576
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.
Abid Mahroz, Sheikh Khizer Sohail, Ahmad Muhammad Shahbaz et al.
Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
PMID: 42552238
GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.
Inamine Susumu, Uesato Yasunori
Diabetes, obesity & metabolism · 2026
PMID: 42474323
GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.
Kennedy Kevin P, Bremseth-Vining Ryan, Lynch Kevin G et al.
The Journal of clinical psychiatry · 2026
PMID: 42280306
GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions-A Systematic Review.
Myśliwczyk Dominika, Gofron Krzysztof Ksawery, Wasilewski Andrzej et al.
Nutrients · 2026
PMID: 42480803
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
Grigson Patricia Sue, Bunce Scott C, Brick Timothy R et al.
Biological psychiatry · 2026
PMID: 42254823
GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes.
Amorim Moreira Alves Gabriel, Teranishi Masatoki, Majumdar Rajendranandini et al.
Chronic diseases and translational medicine · 2026
PMID: 42452454
GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.
Ahmed Faizan, Gohar Najam, Shafqat Madeeha et al.
Journal of clinical medicine · 2026
PMID: 42414609
GLP-1 medications: use and interest in a representative survey of Finns.
Jallinoja Piia Tuuli, Pietiläinen Kirsi H, Chang Virginia W
International journal of obesity (2005) · 2026
PMID: 42269776
GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study.
Ashraf Tanveer, Lessan Nader
Diabetes research and clinical practice · 2026
PMID: 42252247
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.
Hsu A H-C, Ramirez P T, Chang Y-H et al.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026
PMID: 42546112
GLP-1 receptor agonists in hip, knee and shoulder arthroplasty: Implications for obesity, osteoarthritis, metabolic optimisation and complications.
Avram George M, Indelli Pier Francesco, Violante Bruno et al.
Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2026
PMID: 42572056
GLP-1-Based Therapies in Pain Medicine: A Narrative Review and Expert Opinion on Obesity-Related Low Back and Knee Pain.
Hasoon Jamal, Nguyen Anvinh, Viswanath Omar et al.
Current pain and headache reports · 2026
PMID: 42274932
GLP-1-based therapy and ICD-10-documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study.
Loizidis Giorgos, Summer Ross
Clinical rheumatology · 2026
PMID: 42136855
GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives.
Fang Qiujie, Zhu Yipeng, Rao Mei et al.
Frontiers in medicine · 2026
PMID: 42306018
GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review.
Roy Elyzabeth, Parent Marie-Claude, Ducharme Anique
Drugs in context · 2026
PMID: 42210885
GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.
Vu Marie, Schmidt Madelyn, Gandhi Smiti et al.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
PMID: 42543940
Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India.
Saxena Abhyuday, Prakash Anupam
The Journal of the Association of Physicians of India · 2026
PMID: 42569733
Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Heart Failure Outcomes: A Scoping Review of Contemporary Randomized Controlled Trials.
Patel Jenika, Patel Deep, Pino Maria
Cureus · 2026
PMID: 42244136
Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study.
Alkabbani Wajd, Crisafulli Salvatore, Paik Julie M et al.
Diabetes, obesity & metabolism · 2026
PMID: 42292722
Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis.
Muller Ferreira Vicky, Ayres Muller Victor
Cureus · 2026
PMID: 42327438
Glucagon-Like Peptide-1 Receptor Agonists Improve Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction, Independent of Diabetes: A Systematic Review and Meta-Analysis.
Shokravi Arveen, Singh Rishav, Sharma Sohat et al.
CJC open · 2026
PMID: 42133988
Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation.
Fallot Lucas B, Anderson Carol A, Pinc Johnathan R et al.
Journal of the American Chemical Society · 2026
PMID: 42155605
Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis.
Cheng Po-Lung, Chang Hua-Ching
Diabetes research and clinical practice · 2026
PMID: 42131335
Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.
Ciancio Giovanni, Maranini Beatrice, Sandri Gilda et al.
Frontiers in immunology · 2026
PMID: 42250261
Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like-Peptide-1 Use Following 10-Session Cognitive-Behavioural Therapy for Binge-Eating Disorder: A Single-Case Experimental Design.
Dunford Ashley, Yee Stefania, Thomas Jennifer J et al.
European eating disorders review : the journal of the Eating Disorders Association · 2026
PMID: 42249225
Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.
Piraccini Bianca Maria, Vañó-Galván Sergio, Blume-Peytavi Ulrike et al.
Dermatology and therapy · 2026
PMID: 42487660
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
Nejat Cameron, Lin Robert, Addo Daniel et al.
Clinical case reports · 2026
PMID: 42536323
Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.
Pisani Davide, Lorenza Driul, Fordellone Mario et al.
Endocrine · 2026
PMID: 42469142
Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management?
Scilletta Sabrina, Di Marco Maurizio, Bosco Giosiana et al.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026
PMID: 42166309
ICER report demonstrates both the value and challenges in financing of weight loss medications.
Ramachandran Sujith, Urick Ben, Thomas Tara
Journal of managed care & specialty pharmacy · 2026
PMID: 42570075
Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.
Khan Sajjad Ahmed, Marasini Anurag, Shrestha Alisha et al.
Digestive diseases and sciences · 2026
PMID: 42388688
Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan.
Nagayama Daiji, Wakamatsu Miwako, Watanabe Yasuhiro et al.
Obesity pillars · 2026
PMID: 42126155
Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.
Anderson Brady J, Van Daele Douglas J, Claussen Alexander D et al.
The Annals of otology, rhinology, and laryngology · 2026
PMID: 42452840
Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes.
Polsky Sarit, Beck Elizabeth, Shah Archi et al.
Diabetes technology & therapeutics · 2026
PMID: 42568490
Incretin analogues as cardiovascular agents: a state-of-the-art review.
Araiza-Garaygordobil Diego, Rico-Fontalvo Jorge, Hernández-Balbuena Betsabe et al.
Frontiers in endocrinology · 2026
PMID: 42455418
Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.
Khatami Seyedhesamoddin, Faghihi Mohammadsadegh, Tavakoli Ghazal et al.
Cardiovascular toxicology · 2026
PMID: 42382865
Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control.
Hemdev Vaishnavi, Abuzenah Mohammad, Alsaafin Qossay et al.
Cureus · 2026
PMID: 42257115
Indications, efficacy, and safety of glucagon-like peptide-1 receptor agonists in respiratory diseases: A systematic review.
Esmaeel Moudhi N, Esmaeel Nasima N, Alhouli Reem M et al.
Journal of family medicine and primary care · 2026
PMID: 42429876
Influence without medical expertise: a social network analysis of Mounjaro discussions on twitter (X).
AlHazmi Saja, AlRasheed Hayam A, Gomaa Basma
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
PMID: 42307498
Interruption of Early Cardiovascular Risk Pathways With GLP-1-Based Therapy for Obesity.
Everett Brendan M, Ostrominski John W
Journal of the American College of Cardiology · 2026
PMID: 42451041
Ironing Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency.
Infante Marco, Ricordi Camillo, Pacifici Francesca et al.
Nutrients · 2026
PMID: 42273737
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity.
Merola Joseph F, Kartman Cynthia E, Fischer Peter et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2026
PMID: 42139049
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.
Lebwohl Mark, Blauvelt Andrew, Kartman Cynthia E et al.
JAMA dermatology · 2026
PMID: 42299163
Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Makhmutov Alisher, Qureshi Faisal
Cureus · 2026
PMID: 42424921
Lead-guided prodrug development of small molecules as GLP-1R agonists.
Lentschat Hannah, Aboelfotouh Habiba G, Nabil Peter et al.
Bioorganic chemistry · 2026
PMID: 42531456
Letter to the Editor Regarding "Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists".
Wang Joshua
Spine · 2026
PMID: 42206250
Lifestyle First and Lifestyle Always, Does Not Mean Lifestyle Only: Reimagining Cardiometabolic Care in the Era of GLP-1 Receptor Agonists.
Joy Elizabeth, Bonnet Jonathan
American journal of lifestyle medicine · 2026
PMID: 42542974
Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations.
Cotrik Ervin, da Silva Antônio Geraldo, Soares Jair C
International clinical psychopharmacology · 2026
PMID: 42576670
Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI.
Cusi Kenneth, Gastaldelli Amalia, Landó Laura Fernández et al.
Liver international : official journal of the International Association for the Study of the Liver · 2026
PMID: 42318855
Long-term effects of weight-reducing drugs in people with hypertension.
Spary-Kainz Ulrike, Posch Nicole, Radl-Karimi Christina et al.
The Cochrane database of systematic reviews · 2026
PMID: 42208988
Maintaining weight loss with tirzepatide . . . and other research.
Nolan Tom
BMJ (Clinical research ed.) · 2026
PMID: 42418948
Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases.
Li Yufeng, Sheng Hongda, Zhou Tingting et al.
Drug metabolism and disposition: the biological fate of chemicals · 2026
PMID: 42244165
Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens.
Lodrigues Abigail B, Russell Alissa V, Lopez Shelby Tungate et al.
Obesity (Silver Spring, Md.) · 2026
PMID: 42571951
Microdosing Tirzepatide in Multi-Dose Pens: Clinical Individualization, Safety, and Evidence Gaps.
Vidal-Ostos De Lara Fernando
Obesity (Silver Spring, Md.) · 2026
PMID: 42382663
Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.
Simancas-Racines Daniel, Campuzano-Donoso Martín, Rossetti Gianluca et al.
Obesity pillars · 2026
PMID: 42484993
Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
Ryszkiewicz Piotr, Baranowska-Kuczko Marta, Malinowska Barbara et al.
Pharmacological reports : PR · 2026
PMID: 42198465
Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection.
Shin Min Hyeok, Jeong Jin Woo, Ha Se Eun et al.
Pharmaceuticals (Basel, Switzerland) · 2026
PMID: 42420795
Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.
Chen Solomon Chih-Cheng, Wang Tso-Jen, Chou Chu-Kuang et al.
Diabetes, obesity & metabolism · 2026
PMID: 42373755
Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
Huang Yu-Nan, Liu Kai-Wen, Li Pin-Hung et al.
Communications medicine · 2026
PMID: 42280393
Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance.
Zambrano-Villacres Raynier, Campuzano-Donoso Martín, Reytor-González Claudia et al.
Nutrients · 2026
PMID: 42467408
Obese and overweight patients with type 2 diabetes mellitus are not treated optimally - is it time to reconsider clinical practice?
Milardović Tanja Miličević, Cvitković Ivna, Volčanšek Špela et al.
Expert review of clinical pharmacology · 2026
PMID: 42492687
One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
Gao Serena X, Borner Tito
Appetite · 2026
PMID: 42120723
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Aronne Louis J, Horn Deborah B, le Roux Carel W et al.
Nature medicine · 2026
PMID: 42383207
Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.
Malhotra Atul, Gottlieb Daniel J, Kundel Vaishnavi et al.
Contemporary clinical trials communications · 2026
PMID: 42535213
Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
Omura Takuya, Kamihara Takahiro
Cureus · 2026
PMID: 42499401
Papular granuloma annulare associated with tirzepatide: A case report.
Howard Tara, Clichy-Silva Amanda, Kerdel Francisco
JAAD case reports · 2026
PMID: 42424303
Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.
Miller Luke B, Dellen Matthew J, Gilbert Ester J et al.
Military medicine · 2026
PMID: 42449952
Peritoneal Incretin Deficiency and Tirzepatide as a Multi-Axis Adjuvant Hypothesis in Treatment-Refractory Endometriosis: A Mechanistic Framework Linking Metabolism, Immunity, Fibrosis, and Nociception.
Jacobsen Leonardo, Viana Diogo Pinto da Costa, Folador Graciela Morgado et al.
International journal of molecular sciences · 2026
PMID: 42136381
Persistent Adipose Inflammation Despite Metabolic Recovery Reveals Tissue-Specific Immunomodulation by Tirzepatide.
Seo Mihye, Averia Maria, Julietta Vivi et al.
Endocrinology and metabolism (Seoul, Korea) · 2026
PMID: 42487666
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
La Vignera Sandro, Condorelli Rosita A
Journal of the Endocrine Society · 2026
PMID: 42296496
Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026).
Qaseem Amir, Cross J Thomas, Harrod Curtis S et al.
Annals of internal medicine · 2026
PMID: 42557390
Pharmacotherapy in obstructive sleep apnoea: a clinical guide.
Shastry Shashank, Kimoff John R, Pinto Lancelot Mark
Sleep & breathing = Schlaf & Atmung · 2026
PMID: 42307617
Pityriasis Lichenoides et Varioliformis Acuta Associated With Tirzepatide: A First Report.
Deniz Muzaffer Serdar, Sarac Gulhan Aksoy, Celik Burak et al.
Journal of diabetes · 2026
PMID: 42502530
Possible Attenuation of Early Weight Loss During Tirzepatide Therapy in a Patient Treated With Levosulpiride: A Case Report and Mechanistic Hypothesis.
Carducci Augusto, Di Matteo Pierfrancesco, Ferri Claudio et al.
Cureus · 2026
PMID: 42287159
Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.
Node Koichi, Batterham Rachel L, Liu-Seifert Hong et al.
Current medical research and opinion · 2026
PMID: 42534203
Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.
Patel Henna, Babli Shimul A, Shah Shivani et al.
Cureus · 2026
PMID: 42467450
Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.
DiStefano Michael J, Tilley Adeleine, Paratane Deepika et al.
JAMA health forum · 2026
PMID: 42572119
Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
Sattar Naveed, Mamas Mamas, Li Runjia et al.
European journal of preventive cardiology · 2026
PMID: 42131512
Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis.
Ghosal Samit, Sinha Binayak
European heart journal open · 2026
PMID: 42575862
Prescribed but Not Filled: Patient Factors Related to Semaglutide/Tirzepatide Prescription Fills Among Those With Prescription Orders for Obesity Treatment.
Acharya Mahip, Thakur Deboleena
Diabetes, obesity & metabolism · 2026
PMID: 42413499
Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease.
Vear Anika, Olsen Sofie Amalie, Lange Emilie Cathrine Holst et al.
Cell reports. Medicine · 2026
PMID: 42256457
Psychosocial Outcomes in Telemedicine and Long-Acting Incretin-Specific Behavioral Intervention.
Heinberg Leslie J, Lee Alexandra M, Foster Gary D et al.
Obesity science & practice · 2026
PMID: 42244474
Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.
Heisey Henry D, Gregg L Parker, Verrico Christopher D et al.
Diabetes, obesity & metabolism · 2026
PMID: 42383938
Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.
Ghusn Wissam, Fansa Sima, Tama Elif et al.
Mayo Clinic proceedings · 2026
PMID: 42410316
Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.
Berry Simon A, Goodman Iona R, McNally Eleanor et al.
Diabetes, obesity & metabolism · 2026
PMID: 42560020
Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.
Rosenior-Patten Onayomi, Lees Zoe, Rowe Rebecca et al.
Diabetes, obesity & metabolism · 2026
PMID: 42217105
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study.
Takahashi Noriyuki, Ohara Makoto, Yokoyama Hiroki et al.
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
PMID: 42417199
Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review.
Bloomgarden Zachary
Journal of diabetes · 2026
PMID: 42286047
Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity.
Park Junkyu, Shin Sujin, Kim Youngmin et al.
Scientific reports · 2026
PMID: 42457543
Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.
Kitsunai Hiroya, Maruyama Fumika, Miyano Yukie et al.
Endocrine journal · 2026
PMID: 42576608
Real-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis.
Valdez Yllka, Segev Natalie, Parimi Neha et al.
Journal of pediatric endocrinology & metabolism : JPEM · 2026
PMID: 42542297
Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: a prospective study.
Pérez-Pevida Belén, Santana Santana Mónica, Liaño Arriola Cristina et al.
Clinical nutrition ESPEN · 2026
PMID: 42491427
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Gibble Theresa Hunter, Leith Andrea, Harrison Lewis et al.
Obesity pillars · 2026
PMID: 42329593
Residual gastric content after tirzepatide discontinuation: is one week enough?
Hidiroglu Ela E, Altinsoy Savas
Minerva anestesiologica · 2026
PMID: 42479131
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Zeng Lijuan, Zinmon-Htet Celeste, Hundie Tsegaye et al.
Annals of the American Thoracic Society · 2026
PMID: 42297568
SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.
Rutter Martin K, Mount Julie, Gibson J Martin et al.
Obesity (Silver Spring, Md.) · 2026
PMID: 42530340
SURPASS-CVOT and the Emerging Biology of Cardiometabolic Benefit.
Corrao Salvatore, Cosentino Francesco, Federici Massimo
Diabetes, obesity & metabolism · 2026
PMID: 42551699
Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.
Dutta Deep, Jena Sweekruti, Mahajan Kunal et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
PMID: 42290037
Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.
Castaneda Regina, Bechenati Dima, Rivera Gutierrez Rene de J et al.
Obesity (Silver Spring, Md.) · 2026
PMID: 42173727
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
Di Napoli Marissa, Morton Kelly, Evensky Cole et al.
American journal of surgery · 2026
PMID: 42423951
Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.
Pendrey Anna Geraldina, Rivera Sierra Jennyfer Alejandra, Alvarez Lobo Fernando Alberto et al.
Advances in therapy · 2026
PMID: 42381258
Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman.
Abdelshafey Eslam Elsayed, Sewify Khaled, Almutairi Atheer et al.
The American journal of case reports · 2026
PMID: 42573026
Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis.
Khalil Ibrahim, Hossain Md Imran, Akter Mst Mahmuda et al.
Clinical cardiology · 2026
PMID: 42312974
Swiss obesity clinical practice guidance.
Gerber Philipp A, Collet Tinh-Hai, Favre Lucie et al.
Swiss medical weekly · 2026
PMID: 42421979
Targeted Ileal Bile Acid Transporter Inhibition as Rescue Therapy for Tirzepatide-Induced Severe Constipation: A Case Report.
Choudhuri Bodhisatwa
Case reports in gastroenterology · 2026
PMID: 42210892
Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.
Mohseni Yasmine, Vazirnia Aria, Minokadeh Ardalan et al.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
PMID: 42297761
Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network.
Dziewierz Artur, Kulicka Natalia, Stolarska Kaja et al.
Diabetes, obesity & metabolism · 2026
PMID: 42201545
The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions.
Trainer Nicole
Journal of the American Association of Nurse Practitioners · 2026
PMID: 42166683
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms.
Davies Iona, Holst Jens J, Rosenkilde Mette M et al.
Annual review of nutrition · 2026
PMID: 42210891
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
Zarabian Nikkia, Farah Mina, Stines Amanda et al.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
PMID: 42165019
The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.
Lingyu Zhang, Peng Feng, Wanting Zhong et al.
Frontiers in endocrinology · 2026
PMID: 42387290
Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study.
Purcell Amanda R, Longfield Matilda S G, Rodrigo Natassia et al.
Diabetes, obesity & metabolism · 2026
PMID: 42575714
Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis.
Gibble Theresa Hunter, Venkataraman Malvika, Mojdami Donna et al.
Diabetes, obesity & metabolism · 2026
PMID: 42330097
Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells.
Ren Lu, Belbachir Nadjet, Zhang Hao et al.
Circulation · 2026
PMID: 42572932
Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults.
Su Yu-Jung, Gau Shuo-Yan, Shiue Yow-Ling
Clinical pharmacology and therapeutics · 2026
PMID: 42115707
Tirzepatide Versus Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes With Established Cardiovascular Disease: An Indirect Treatment Comparison Meta-Analysis.
Goldenberg Ronald M, Trinacty Jill, Ibrahim Christine
Diabetes, obesity & metabolism · 2026
PMID: 42326175
Tirzepatide and Cardiometabolic Effects in Obese Non-diabetic Adults: A Systematic Review, Meta-Analysis, and Narrative Synthesis of Cardiovascular Outcomes.
Chaparala Pravalya, Aravind Rongali Dinesh, Khot Maha et al.
Cureus · 2026
PMID: 42533465
Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.
Mohamed Zakariye Isak, Shidane Abdinasir Adam, Abdiasis Abdullahi Mohamud et al.
Endocrinology, diabetes & metabolism · 2026
PMID: 42460324
Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.
Kahkedjian Fredy, Shah Jaffer, Kreidieh Firas
Frontiers in endocrinology · 2026
PMID: 42426654
Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study.
Wu Jheng-Yan, Lee Keng-Wei, Huang Sheng-Chi et al.
BMC cardiovascular disorders · 2026
PMID: 42317617
Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence.
Parlati Antonio Lm, Martini Luca, Nardi Ermanno et al.
Clinical Medicine Insights. Cardiology · 2026
PMID: 42499664
Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives.
Cadena-Ullauri Santiago, Cadena Paredes Andrés S, Guamán-Herrera Lenín et al.
Frontiers in microbiology · 2026
PMID: 42387035
Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.
Khan Irshad, Meenakshi Sarasa, Abubakar Md et al.
Endocrine · 2026
PMID: 42464302
Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study.
Galasso Martina, Verde Ludovica, Patrone Renato et al.
Journal of translational medicine · 2026
PMID: 42119472
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Zhang Yan, Li Ling
Tissue & cell · 2026
PMID: 42154338
Tirzepatide attenuates neurotoxicity by suppressing inflammation, apoptosis and restoring neurotrophin expression in an Alzheimer's disease-like rat model.
Attia Mohamed S M, Ahmad Sheikh F, Nadeem Ahmed et al.
Metabolic brain disease · 2026
PMID: 42201797
Tirzepatide data: safety always comes first!
Janić Miodrag, Rabbani Syed Arman, El-Tanani Mohamed et al.
Expert opinion on drug safety · 2026
PMID: 42247124
Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.
Vinciguerra Federica, Di Stefano Carla, Guccione Fabio et al.
Obesity surgery · 2026
PMID: 42119587
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Horn Deborah B, Aronne Louis J, Wharton Sean et al.
Lancet (London, England) · 2026
PMID: 42245471
Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome.
Liao X Charlene, Huang Tao, Hong David S et al.
JCEM case reports · 2026
PMID: 42538551
Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report.
Lechner Benjamin, Lechner Katharina, Freibothe Ines et al.
Cardiovascular diabetology. Endocrinology reports · 2026
PMID: 42296968
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).
Yin Yaqi, Ma Jianhua, Liu Dexue et al.
Med (New York, N.Y.) · 2026
PMID: 42379268
Tirzepatide versus conventional GLP-1 receptor agonists for treatment simplification in type 2 diabetes mellitus: a real-world study.
Sawamura Toshitaka, Maeno Misato, Nishimoto Yuya et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
PMID: 42495981
Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report.
Rantanen Rebekka, Olson Christopher, Raval Chirag
Journal of clinical psychopharmacology · 2026
PMID: 42124821
Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study.
Agrawal Prabhat Kumar, Samajdar Shambo Samrat, Garg Ruchika et al.
Journal of mid-life health · 2026
PMID: 42334912
Tirzepatide.
Brož Jan, Koželuhová Marika, Michalec Juraj et al.
Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2026
PMID: 42128641
Top studies of 2025 relevant to primary care: From the PEER team.
Moe Samantha S, Perry Danielle, Thomas Betsy S et al.
Canadian family physician Medecin de famille canadien · 2026
PMID: 42124020
Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.
Pineda-Wieselberg Ronaldo José, Soares Andressa Heimbecher, Napoli Thiago Fraga et al.
Nutrients · 2026
PMID: 42275598
Towards Sustainable Synthesis of Peptide Therapeutics via Tag-Assisted Peptide Synthesis and Aryl Selenoester Aminolysis Ligation.
Egelund Peter H G, Rachid Ayman, Ayoub Anthony et al.
Journal of the American Chemical Society · 2026
PMID: 42465136
Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.
Khalil Waqas, Bibi Khadija, Fareed Tauheed et al.
Cureus · 2026
PMID: 42250233
Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review.
Horne Michael Paul, Pollard Hannah, Day Heather et al.
Journal of the American Association of Nurse Practitioners · 2026
PMID: 42209262
Weight Management With Semaglutide and Tirzepatide in U.S. Adults: Projected Impact on Obesity Prevalence and Heart Failure Risk.
Choi Hailey, Hwang Andrew Y
Diabetes, obesity & metabolism · 2026
PMID: 42382138
Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study.
Gillikin Andrew, Lee Yung, Varney Catherine et al.
EClinicalMedicine · 2026
PMID: 42163990
Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network.
Murugadoss Karthik, Varma Gowtham, Venkatakrishnan A J et al.
Biology methods & protocols · 2026
PMID: 42311474
Weight-loss dynamics with tirzepatide versus semaglutide.
Venkatakrishnan A J, Murugadoss Karthik, Soundararajan Venky
PNAS nexus · 2026
PMID: 42536830
[An historical overview of GLP-1/GIP incretins. From hormone to "swiss-army knife" medications].
Portha Bernard
Biologie aujourd'hui · 2026
PMID: 42169518
[Glucagon-like peptide-1 agonists and heart failure].
Soborun Nisha, Favre Lucie, Lu Henri et al.
Revue medicale suisse · 2026
PMID: 42162470
[Individualizing antihypertensive therapy in diabetes mellitus. Guidelines of the Austrian Diabetes Association (Update 2026)].
Saely Christoph H, Schernthaner Gerit-Holger, Brix Johanna Maria et al.
Wiener klinische Wochenschrift · 2026
PMID: 42162469
[Obesity and type 2 diabetes mellitus (Update 2026)].
Brix Johanna M, Clodi Martin, Harreiter Jürgen et al.
Wiener klinische Wochenschrift · 2026
PMID: 42545321
[Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide].
Troshina E A, Antsiferov M B, Ametov A S et al.
Problemy endokrinologii · 2026
For research use only. This index links to third-party literature. Nothing here constitutes medical advice.